Bio-Techne Stock

Bio-Techne Current Liabilities

The Current Liabilities of Bio-Techne (TECH) as of Sep 3, 2026 is 160.11 M USD. In the previous year, Current Liabilities was 238.06 M USD — a change of -32.75% (lower).

Current Liabilities

160.11 MUSD

YoY

-32.75%

Last updated:

Current Liabilities of Bio-Techne is 2026 160.11 M USD. Current Liabilities of Bio-Techne was 2025 238.06 M USD. It decreases by -32.75% lower compared to the previous year.

The Bio-Techne Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
154.64 M USD
Jan 1, 2020
153.44 M USD
Jan 1, 2021
218.65 M USD
Jan 1, 2022
243.67 M USD
Jan 1, 2023
156.22 M USD
Jan 1, 2024
215.37 M USD
Jan 1, 2025
238.06 M USD
Jan 1, 2026
160.11 M USD
The Bio-Techne Current Liabilities history
YEARCurrent LiabilitiesYoY
160.11 MUSD-32.75%
238.06 MUSD+10.54%
215.37 MUSD+37.86%
156.22 MUSD-35.89%
243.67 MUSD+11.44%
218.65 MUSD+42.50%
153.44 MUSD-0.77%
154.64 MUSD+32.48%
116.72 MUSD-34.60%
178.47 MUSD+139.08%
74.65 MUSD+34.95%
55.32 MUSD+52.83%
36.20 MUSD-16.62%
43.41 MUSD+16.69%
37.20 MUSD+84.35%
20.18 MUSD+17.40%
17.19 MUSD+11.06%
15.48 MUSD-46.33%
28.84 MUSD+24.34%
23.19 MUSD-4.42%
24.27 MUSD+20.63%
20.12 MUSD+10.78%
18.16 MUSD+31.51%
13.81 MUSD-25.48%
18.53 MUSD-2.94%
19.09 MUSD+16.69%
16.36 MUSD+3.55%
15.80 MUSD+68.09%
9.40 MUSD+40.30%
6.70 MUSD+0.00%
6.70 MUSD+21.82%
5.50 MUSD+17.02%
4.70 MUSD+30.56%
3.60 MUSD+5.88%
3.40 MUSD+17.24%
2.90 MUSD+16.00%
2.50 MUSD+25.00%
2.00 MUSD
Access this data via the Eulerpool API

Bio-Techne Stock analysis

What does Bio-Techne do? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Techne stock

Current Liabilities of Bio-Techne is 160.11 M USD in 2026.

Current Liabilities of Bio-Techne changed from 238.06 M USD to 160.11 M USD, representing a -32.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Bio-Techne since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Bio-Techne historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Bio-Techne

All Key Metrics — Bio-Techne